Diamyd Medical

1.20 SEK

0.00 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

0.00 %
-21.31 %
-92.65 %
-89.31 %
-88.22 %
-86.88 %
-93.54 %
-95.44 %
-59.90 %

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

Read more
Market cap
186.6M SEK
Turnover
1.75M SEK
Revenue
130K
EBIT %
-140,953.85 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24/6
2026

Interim report Q3'26

7/10
2026

Annual report '26

3/12
2026

General meeting '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
The intention was to publish the report before the readout, but the new financing package complicated things so much that practically everything had to be recalculated and models updated. On the other hand, the new financing package combined with market movements led to a heuristically...
3/30/2026, 2:53 PM
by Gubrick
9
To all you investors who believed in diabetes treatment drugs and lost your money in Diamyd, I recommend turning your gaze to a company called Nektar - $NKTR. They have a very interesting diabetes trial underway with a drug that targets Tregs, aiming to restore the body’s own immune...
4/23/2026, 11:15 AM
by SeekingAlpha
8
New information has come out, nothing positive. diamyd.com Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming...
4/10/2026, 6:40 PM
6
There’s no point in selling in this bankruptcy. It still amazes me how the difference can be so radical compared to previous data that it’s not even worth continuing the study to the end. The probability that previous positive results were just a coincidence is quite small, isn’t...
4/13/2026, 9:38 AM
4
Good to know, the expenses stop running and they can do the trial’s autopsy. I’ll hold the earthly remains of the position out of academic interest.
4/10/2026, 7:28 PM
by Clark kent
4
Ulf stepped down from the CEO role after ten years. He was replaced by Diamyd founder, chairman of the board, and former CEO, Anders Essen-Möller. Anders is already a respectable 85 years old and founded Diamyd when his daughter fell ill with type 1 diabetes. A recent interview about...
4/27/2026, 11:35 AM
3
Rose Garden seems to understand option pricing clearly better than average and even tipped off beforehand that they had sold warrants, so props for that. I had a 0.7% position in the warrant… On the other hand, seeking financing before this reading was an excellent move by management...
3/30/2026, 12:05 PM
by Clark kent
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.